6533b82efe1ef96bd12925b2
RESEARCH PRODUCT
P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma
Ken KatoH. CastroTobias ArkenauJ. WangCrystal S. DenlingerY.-j. BangJ. TaberneroMarkus MoehlerJ. LiR. Xusubject
Chemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologyGastroesophageal Junction AdenocarcinomaPlaceboGastroenterologyFirst line therapyOncologyInternal medicinemedicineIn patientbusinessyear | journal | country | edition | language |
---|---|---|---|---|
2020-07-01 | Annals of Oncology |